Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;40(10):1385-1389.
doi: 10.1016/j.vaccine.2021.12.060. Epub 2022 Feb 8.

Cutaneous CpG adjuvant conditioning to enhance vaccine responses

Douglas A Carlow  1 , Jacqueline C Y Lai  2 , Tobias R Kollmann  3 , Manish Sadarangani  4 , Jan P Dutz  5
Affiliations

Cutaneous CpG adjuvant conditioning to enhance vaccine responses

Douglas A Carlow et al. Vaccine. .

Abstract

Adjuvant activity of the Toll receptor 9 agonist CpG 1826 was compared when given subcutaneously (s.c.) together with ovalbumin (s.c.[CpG + Ova]), or when given by either s.c. or intradermally (i.d.) routes two days prior to s.c. ovalbumin. Frequencies of CD8 + effector (TEFF) and central memory (TCM) T cells along with total IgG, IgG2c, and IgG1 titres were measured to ascertain how timing and location of CpG conditioning influenced vaccination outcome. Prior treatment with CpG enhanced TEFF, TCM, as well as total IgG responses. TEFF and TCM responses were greatest when CpG was given intradermally and prior to s.c. ovalbumin, conditions that eliminated the fraction of TCM 'non-responders' observed after s.c.[CpG + Ova] vaccination. IgG responses were polarized toward IgG2c after early s.c. CpG but toward IgG1 after early i.d. CpG. Separating CpG adjuvant and antigen application in time and space can improve vaccination outcome.

Keywords: CD8+ T cells; Conditioning; CpG; Innate immunity; Intradermal immunization; Skin.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Manish Sadarangani reports a relationship with GlaxoSmithKline that includes: funding grants. Manish Sadarangani reports a relationship with Merck & Co Inc that includes: funding grants. Manish Sadarangani reports a relationship with Pfizer that includes: funding grants. Manish Sadarangani reports a relationship with Sanofi Pasteur Inc that includes: funding grants. Manish Sadarangani reports a relationship with Seqirus Inc. that includes: funding grants. Manish Sadarangani reports a relationship with Symvivo that includes: funding grants. Manish Sadarangani reports a relationship with VBI Vaccines Inc that includes: funding grants..

Publication types

Grants and funding